Stay updated on Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial page.

Latest updates to the Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study descriptions and inclusion criteria for a clinical trial on Low-Grade Serous Ovarian Cancer, while adding references to the study's collaborators and a new version revision number.SummaryDifference14%
- Check39 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 29, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.4%
- Check46 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check82 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check97 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
Stay in the know with updates to Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avutometinib Alone vs Combo in Low-Grade Serous Ovarian Cancer Clinical Trial page.